p(HGNC:GSK3A)

Entity

Name

GSK3A

Namespace

HGNC

Namespace Version

20180215

Namespace URL

https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hgnc/hgnc-20180215.belns

Tau oligomers and tau toxicity in neurodegenerative disease by Ward et al., 2012

However, when tau aggregates, this conformation is altered, exposing PAD and allowing activation of the PP1/GSK3 signalling pathway facilitating FAT inhibition [21] PubMed:22817713

Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. PubMed:30640040

Further investigation illustrated that this inhibition occurs via activation of a signalling cascade involving PP1 (protein phosphatase 1) and GSK3 (glycogen synthase kinase 3) [24] PubMed:22817713

Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. PubMed:30640040

Stimulation of GSK3β but not GSK3α promoted BACE1 gene expression and BACE1-mediated APP processing in vitro by regulating BACE1 gene promoter activity, which was dependent on NF-κB p65-binding elements in the BACE1 pro- moter [51]. PubMed:27288790